Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ)verified

EGTX.ST

Price:

$4.635

Market Cap:

$1.66B

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics...[Read more]

Industry

Biotechnology

IPO Date

2011-04-07

Stock Exchange

STO

Ticker

EGTX.ST

The PE Ratio as of December 2025 (TTM) for Egetis Therapeutics AB (publ) (EGTX.ST) is -5.15

According to Egetis Therapeutics AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -5.15. This represents a change of -8.73% compared to the average of -5.64 of the last 4 quarters.

Egetis Therapeutics AB (publ) (EGTX.ST) Historical PE Ratio (quarterly & annually)

How has EGTX.ST PE Ratio performed in the past?

The mean historical PE Ratio of Egetis Therapeutics AB (publ) over the last ten years is -12.25. The current -5.15 PE Ratio has changed 4.10% with respect to the historical average. Over the past ten years (40 quarters), EGTX.ST's PE Ratio was at its highest in in the March 2019 quarter at 12.79. The PE Ratio was at its lowest in in the March 2016 quarter at -56.07.

Quarterly (TTM)
Annual

Average

-12.25

Median

-10.83

Minimum

-34.00

Maximum

-3.06

Egetis Therapeutics AB (publ) (EGTX.ST) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Egetis Therapeutics AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 276.30%

Maximum Annual PE Ratio = -3.06

Minimum Annual Increase = -83.52%

Minimum Annual PE Ratio = -34.00

Quarterly (TTM)
Annual
YearPE RatioChange
2024-6.2442.49%
2023-4.38-39.78%
2022-7.28-36.86%
2021-11.53276.30%
2020-3.06-83.52%
2019-18.5983.49%
2018-10.13-17.24%
2017-12.24-18.66%
2016-15.05-55.74%
2015-34.00118.59%

Egetis Therapeutics AB (publ) (EGTX.ST) Average PE Ratio

How has EGTX.ST PE Ratio performed in the past?

The current PE Ratio of Egetis Therapeutics AB (publ) (EGTX.ST) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

-5.97

5-year avg

-6.50

10-year avg

-12.25

Egetis Therapeutics AB (publ) (EGTX.ST) PE Ratio vs. Peers

How is EGTX.ST’s PE Ratio compared to its peers?

Egetis Therapeutics AB (publ)’s PE Ratio is greater than BioInvent International AB (publ) (-5.86), greater than Vicore Pharma Holding AB (publ) (-5.68), less than Saniona AB (publ) (12.04), less than Hansa Biopharma AB (publ) (-4.42), greater than Diamyd Medical AB (publ) (-7.79), less than Oncopeptides AB (publ) (-4.50), less than Humana AB (publ) (9.81), greater than SynAct Pharma AB (-10.23), greater than Devyser Diagnostics AB (publ) (-71.31), greater than Xspray Pharma AB (publ) (-5.66),

Build a custom stock screener for Egetis Therapeutics AB (publ) (EGTX.ST) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Egetis Therapeutics AB (publ) using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Egetis Therapeutics AB (publ) (EGTX.ST) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Egetis Therapeutics AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Egetis Therapeutics AB (publ)'s PE Ratio?

How is the PE Ratio calculated for Egetis Therapeutics AB (publ) (EGTX.ST)?

What is the highest PE Ratio for Egetis Therapeutics AB (publ) (EGTX.ST)?

What is the 3-year average PE Ratio for Egetis Therapeutics AB (publ) (EGTX.ST)?

What is the 5-year average PE Ratio for Egetis Therapeutics AB (publ) (EGTX.ST)?

How does the current PE Ratio for Egetis Therapeutics AB (publ) (EGTX.ST) compare to its historical average?